NASDAQ: ADILAdial Pharmaceuticals Inc Stock
$2.85-0.13 (-4.36%)
Updated Jun 15, 2026
ADIL Price
$2.85
Fair Value Price
$8.80
Market Cap
$6.11M
52 Week Low
$1.31
52 Week High
$18.90
P/E
-0.33x
P/B
1.64x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$7.77M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.41
Operating Cash Flow
-$7M
Beta
0.79
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ADIL Overview
Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its primary investigational compound, AD04, functions as a selective serotonin-3 antagonist and is currently undergoing pivotal Phase III clinical trials for the treatment of alcohol use disorder. Beyond this flagship product, the company is also exploring drug candidates aimed at providing non-opioid pain relief and addressing a range of other medical conditions. Established in 2010, Adial Pharmaceuticals, Inc. is headquartered in Charlottesville, Virginia.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ADIL's potential to beat the market
- ADIL doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ADIL
RankedUnranked of 462
RankedUnranked of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $230.59 | A | |
| $53.00 | A | |
| $16.00 | A |
Be the first to know about important ADIL news, forecast changes, insider trades & much more!
ADIL News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ADIL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ADIL ($2.85) is undervalued by 67.6% relative to our estimate of its Fair Value price of $8.80 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ADIL ($2.85) is significantly undervalued by 67.6% relative to our estimate of its Fair Value price of $8.80 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
ADIL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ADIL due diligence checks available for Premium users.
Valuation
ADIL fair value
Fair Value of ADIL stock based on Discounted Cash Flow (DCF)
Price
$2.85
Fair Value
$8.80
Undervalued by
67.60%
ADIL ($2.85) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ADIL ($2.85) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ADIL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ADIL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.33x
Industry
16.41x
Market
14.3x
ADIL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.64x
Industry
4.89x
ADIL is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ADIL's financial health
Profit margin
Revenue
$0.0
Net Income
-$2.0M
Profit Margin
0%
ADIL's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$5.2M
Liabilities
$1.5M
Debt to equity
0.41
ADIL's short-term assets ($4.80M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ADIL's short-term assets ($4.80M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ADIL's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ADIL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.6M
Investing
$0.0
Financing
$315.3k
ADIL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ADIL vs Biotech Stocks
Adial Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.